PubRank

Ruiwen Zhang

Author PubWeight™ 94.52‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol 2006 2.33
2 MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem 2004 1.93
3 Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A 2003 1.87
4 MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 2005 1.83
5 Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets 2004 1.72
6 Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J 2008 1.65
7 Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 2007 1.60
8 The MDM2-p53 pathway revisited. J Biomed Res 2013 1.52
9 Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 2005 1.51
10 Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 2008 1.47
11 Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today 2008 1.37
12 Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure-Activity Relationships, and Molecular Mechanisms of Action. Front Pharmacol 2012 1.35
13 RYBP stabilizes p53 by modulating MDM2. EMBO Rep 2008 1.33
14 Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med 2008 1.32
15 Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate 2008 1.31
16 p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets 2005 1.30
17 Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res 2005 1.30
18 Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res 2004 1.25
19 Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate 2003 1.22
20 Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res 2006 1.22
21 MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer 2013 1.17
22 In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res 2009 1.13
23 Differential effects of ginsenosides on NO and TNF-alpha production by LPS-activated N9 microglia. Int Immunopharmacol 2006 1.13
24 Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2. PLoS One 2012 1.09
25 Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett 2009 1.07
26 Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther 2006 1.05
27 Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer 2009 1.00
28 Knockdown of ribosomal protein S7 causes developmental abnormalities via p53 dependent and independent pathways in zebrafish. Int J Biochem Cell Biol 2011 1.00
29 Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications. Med Res Rev 2014 0.98
30 Anti-Inflammatory Agents for Cancer Therapy. Mol Cell Pharmacol 2009 0.98
31 Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res 2003 0.98
32 Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP. Clin Cancer Res 2012 0.97
33 Experimental therapy of ovarian cancer with synthetic makaluvamine analog: in vitro and in vivo anticancer activity and molecular mechanisms of action. PLoS One 2011 0.96
34 miRNAs in cancer prevention and treatment and as molecular targets for natural product anticancer agents. Curr Cancer Drug Targets 2013 0.96
35 A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action. Breast Cancer Res Treat 2009 0.95
36 Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics. Mol Pharm 2011 0.94
37 Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res 2004 0.94
38 Recent advances in validating MDM2 as a cancer target. Anticancer Agents Med Chem 2009 0.94
39 FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. Invest New Drugs 2009 0.93
40 Synthesis and in vitro anti-lung cancer activity of novel 1, 3, 4, 8-tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogs. Med Chem 2009 0.93
41 Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine. Cancer Chemother Pharmacol 2004 0.93
42 Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents. Mol Cancer Ther 2013 0.91
43 Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther 2006 0.91
44 Preclinical evaluation of anticancer efficacy and pharmacological properties of FBA-TPQ, a novel synthetic makaluvamine analog. Mar Drugs 2012 0.91
45 MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change. J Biol Chem 2010 0.90
46 Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics. Curr Pharm Des 2005 0.90
47 Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem Biophys Res Commun 2002 0.90
48 Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms. Mol Med 2002 0.90
49 Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Int J Oncol 2007 0.90
50 Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PLoS One 2008 0.90
51 Transcription factor NFAT1 activates the mdm2 oncogene independent of p53. J Biol Chem 2012 0.88
52 Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy. Cancer Chemother Pharmacol 2008 0.87
53 A downstream kinase of the mammalian target of rapamycin, p70S6K1, regulates human double minute 2 protein phosphorylation and stability. J Cell Physiol 2006 0.87
54 KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. PLoS One 2012 0.86
55 Extracellular activity of cyclic AMP-dependent protein kinase as a biomarker for human cancer detection: distribution characteristics in a normal population and cancer patients. Cancer Epidemiol Biomarkers Prev 2007 0.86
56 Mode conversion based on forward stimulated Brillouin scattering in a hybrid phononic-photonic waveguide. Opt Express 2014 0.85
57 JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21. PLoS One 2012 0.85
58 Experimental therapy for lung cancer: umbilical cord-derived mesenchymal stem cell-mediated interleukin-24 delivery. Curr Cancer Drug Targets 2013 0.85
59 Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. Int J Oncol 2002 0.85
60 Radiolabeled 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2'-fluoro-5-methyldeoxyuracil-beta -D-arabinofuranoside (FMAU) as tumor-imaging agents in mice. Cancer Chemother Pharmacol 2002 0.85
61 CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. Biochem Biophys Res Commun 2003 0.85
62 Japonicone A suppresses growth of Burkitt lymphoma cells through its effect on NF-κB. Clin Cancer Res 2013 0.84
63 Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction. J Biomed Res 2013 0.84
64 Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells. Mol Cancer Ther 2013 0.84
65 Antisense-based cancer therapeutics: are we there yet? Expert Opin Emerg Drugs 2006 0.84
66 T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling. Prostate 2008 0.84
67 Pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from Panax ginseng, in athymic mice bearing xenografts of human pancreatic tumors. Eur J Drug Metab Pharmacokinet 2010 0.83
68 Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. Carcinogenesis 2013 0.83
69 Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol 2007 0.83
70 Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent. Mar Drugs 2010 0.83
71 Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms. Ann N Y Acad Sci 2003 0.83
72 Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy. Prostate 2006 0.82
73 Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme. Anticancer Res 2002 0.81
74 Oncogenes as novel targets for cancer therapy (part III): transcription factors. Am J Pharmacogenomics 2005 0.81
75 Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial. Lung Cancer 2002 0.81
76 Novel MDM2 p53-independent functions identified through RNA silencing technologies. Ann N Y Acad Sci 2005 0.80
77 Oncogenes as novel targets for cancer therapy (part IV): regulators of the cell cycle and apoptosis. Am J Pharmacogenomics 2005 0.80
78 Advances in translational pharmacological investigations in identifying and validating molecular targets of natural product anticancer agents. Curr Cancer Drug Targets 2013 0.80
79 Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ. Curr Cancer Drug Targets 2013 0.79
80 Mesenchymal stem cells modified to express lentivirus TNF-α Tumstatin(45-132) inhibit the growth of prostate cancer. J Cell Mol Med 2011 0.79
81 Recent advances in experimental molecular therapeutics for malignant gliomas. Curr Med Chem Anticancer Agents 2004 0.79
82 Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents. Cancer Chemother Pharmacol 2005 0.79
83 Overexpression of annexin a1 induced by terephthalic acid calculi in rat bladder cancer. Proteomics 2007 0.78
84 Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent. Cancer Chemother Pharmacol 2012 0.78
85 Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms. Int J Oncol 2002 0.78
86 Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent. Cancer Chemother Pharmacol 2005 0.77
87 Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. Cancer Chemother Pharmacol 2005 0.77
88 Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice. Biomed Chromatogr 2014 0.77
89 Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules. Am J Pharmacogenomics 2005 0.77
90 A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors. Cancer Chemother Pharmacol 2007 0.76
91 Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases. Am J Pharmacogenomics 2005 0.76
92 Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl. Cancer Chemother Pharmacol 2005 0.75
93 Antisense approaches in drug discovery and development. Prog Drug Res 2005 0.75
94 Analysis of threshold current of uniaxially tensile stressed bulk Ge and Ge/SiGe quantum well lasers. Opt Express 2017 0.75
95 Anti-cancer molecular targets of natural products. Curr Cancer Drug Targets 2013 0.75
96 Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases. Methods Mol Biol 2015 0.75
97 Design and analysis of a CMOS-compatible distributed Bragg reflector laser based on highly uniaxial tensile stressed germanium. Opt Express 2017 0.75
98 Determination of desoxyepothilone B in nude mice plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal 2006 0.75
99 Analysis of acousto-optic interaction based on forward stimulated Brillouin scattering in hybrid phononic-photonic waveguides. Opt Express 2016 0.75